Overview

Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.
Phase:
Phase 2
Details
Lead Sponsor:
ICON Bioscience Inc